{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:58:38Z","timestamp":1791280718902,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.2515\/therapie\/2015027","type":"journal-article","created":{"date-parts":[[2015,6,26]],"date-time":"2015-06-26T08:09:52Z","timestamp":1435306192000},"page":"443-453","source":"Crossref","is-referenced-by-count":36,"title":["Utilisation en France du baclof\u00e8ne dans l\u2019alcoolod\u00e9pendance de 2007 \u00e0 2013 : \u00e9tude \u00e0 partir du SNIIRAM et du PMSI"],"prefix":"10.1016","volume":"70","author":[{"given":"Christophe","family":"Chaignot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Weill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Ricordeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Alla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.2515\/therapie\/2015027_bb0615","first-page":"58","article-title":"Ability of baclofen in reducing alcohol intake and withdrawal severity: I--Preclinical evidence","volume":"24","author":"Colombo","year":"2000","journal-title":"Alcohol Clin Exp Res"},{"key":"10.2515\/therapie\/2015027_bb0620","first-page":"67","article-title":"Ability of baclofen in reducing alcohol craving and intake: II--Preliminary clinical evidence","volume":"24","author":"Addolorato","year":"2000","journal-title":"Alcohol Clin Exp Res"},{"key":"10.2515\/therapie\/2015027_bb0625","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/alcalc\/37.5.504","article-title":"Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study","volume":"37","author":"Addolorato","year":"2002","journal-title":"Alcohol Alcohol"},{"key":"10.2515\/therapie\/2015027_bb0630","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/alcalc\/agh130","article-title":"Complete and prolonged suppression of symptoms and consequences of alcohol-dependence using high-dose baclofen: a self-case report of a physician","volume":"40","author":"Ameisen","year":"2005","journal-title":"Alcohol Alcohol"},{"key":"10.2515\/therapie\/2015027_bb0635","series-title":"Le dernier verre","author":"Ameisen","year":"2008"},{"key":"10.2515\/therapie\/2015027_bb0640","series-title":"The end of my addiction","author":"Ameisen","year":"2008"},{"key":"10.2515\/therapie\/2015027_bb0645","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(07)61814-5","article-title":"Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomized, double-blind controlled study","volume":"370","author":"Addolorato","year":"2007","journal-title":"Lancet"},{"key":"10.2515\/therapie\/2015027_bb0650","first-page":"48","article-title":"A study of comparative efficacy of baclofen vs acamprosate in reducing alcohol craving and abuse","volume":"17","author":"Mishra","year":"2010","journal-title":"The Orissa J of Psychiatry"},{"key":"10.2515\/therapie\/2015027_bb0655","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1111\/j.1530-0277.2010.01273.x","article-title":"Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial","volume":"34","author":"Garbutt","year":"2010","journal-title":"Alcohol Clin Exp Res"},{"key":"10.2515\/therapie\/2015027_bb0660","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1093\/alcalc\/agr017","article-title":"Dose-response effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial","volume":"46","author":"Addolorato","year":"2011","journal-title":"Alcohol Alcohol"},{"key":"10.2515\/therapie\/2015027_bb0665","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1093\/alcalc\/ags028","article-title":"Abstinence and \u2018low-risk\u2019 consumption 1 year after the initiation of high-dose baclofen: a retrospective study among \u2018high-risk\u2019 drinkers","volume":"47","author":"Rigal","year":"2012","journal-title":"Alcohol Alcohol"},{"key":"10.2515\/therapie\/2015027_bb0670","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3389\/fpsyt.2012.00103","article-title":"Suppression of alcohol dependence using baclofen: a 2-year observational study of 100 patients","volume":"3","author":"de Beaurepaire","year":"2012","journal-title":"Front Psychiatry"},{"key":"10.2515\/therapie\/2015027_bb0675","series-title":"Efficacy and safety of baclofen for maintenance of abstinence in alcohol dependent patients","author":"ALPADIR","year":"2012"},{"key":"10.2515\/therapie\/2015027_bb0680","unstructured":"BACLOVILLE. Traitement de l\u2019alcoolisme - Essai th\u00e9rapeutique pragmatique randomis\u00e9, en double insu pendant un an en milieu ambulatoire du baclof\u00e8ne versus placebo. Essai clinique, NCT01604330, France 2012 https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01604330?term=bacloville&rank=1 Consult\u00e9 le 10 mars 201"},{"key":"10.2515\/therapie\/2015027_bb0685","unstructured":"EU Clinical Trials Register https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search Consult\u00e9 le 10 mars 2015."},{"issue":"5","key":"10.2515\/therapie\/2015027_bb0690","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2515\/therapie\/2014038","article-title":"Efficacy of baclofen on abstinence and craving in alcohol-dependent patients: a meta-analysis of randomized controlled trials","volume":"69","author":"Lesouef","year":"2014","journal-title":"Therapie"},{"key":"10.2515\/therapie\/2015027_bb0695","unstructured":"ANSM. Recommandation temporaire d\u2019utilisation (RTU) du baclof\u00e8ne dans l\u2019alcoolod\u00e9pendance. http:\/\/ansm.sante.fr\/var\/ansm_site\/storage\/original\/application\/5478accaf69e1a0f97987c9eeb9b9347.pdf Consult\u00e9 le 10 mars 2015 (64 pages)."},{"key":"10.2515\/therapie\/2015027_bb0700","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1093\/eurpub\/ckt015","article-title":"Alcohol-attributable mortality in France","volume":"23","author":"Gu\u00e9rin","year":"2013","journal-title":"Eur J Public Health"},{"key":"10.2515\/therapie\/2015027_bb0705","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0140-6736(09)60746-7","article-title":"Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders","volume":"373","author":"Rehm","year":"2009","journal-title":"Lancet"},{"issue":"1","key":"10.2515\/therapie\/2015027_bb0710","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/alcalc\/36.1.89","article-title":"Two methods of estimating health costs linked to alcoholism in France (with a note on social costs)","volume":"36","author":"Reynaud","year":"2001","journal-title":"Alcohol Alcohol"},{"key":"10.2515\/therapie\/2015027_bb0715","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1001\/jama.2014.3628","article-title":"Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis","volume":"311","author":"Jonas","year":"2014","journal-title":"JAMA"},{"issue":"2","key":"10.2515\/therapie\/2015027_bb0720","doi-asserted-by":"crossref","first-page":"e87366","DOI":"10.1371\/journal.pone.0087366","article-title":"Disulfiram efficacy in the treatment of alcohol dependence: a meta-analysis","volume":"9","author":"Skinner","year":"2014","journal-title":"PLoS One"},{"issue":"8","key":"10.2515\/therapie\/2015027_bb0725","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/archpsyc.56.8.719","article-title":"A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence","volume":"56","author":"Mason","year":"1999","journal-title":"Arch Gen Psychiatry"},{"issue":"11","key":"10.2515\/therapie\/2015027_bb0730","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.euroneuro.2013.02.006","article-title":"A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence","volume":"23","author":"Gual","year":"2013","journal-title":"Eur Neuropsychopharmacol"},{"issue":"8","key":"10.2515\/therapie\/2015027_bb0735","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.biopsych.2012.10.020","article-title":"Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene","volume":"73","author":"Mann","year":"2013","journal-title":"Biol Psychiatry"},{"key":"10.2515\/therapie\/2015027_bb0740","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1093\/alcalc\/agt061","article-title":"Efficacy of as-needed nalmefene in alcohol-dependent patients with at least a high drinking risk level: results from a subgroup analysis of two randomized controlled 6-month studies","volume":"48","author":"Van den Brink","year":"2013","journal-title":"Alcohol Alcohol"},{"key":"10.2515\/therapie\/2015027_bb0745","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.respe.2010.04.005","article-title":"French national health insurance information system and the permanent beneficiaries sample","volume":"58","author":"Tuppin","year":"2010","journal-title":"Rev Epidemiol Sante Publique"},{"key":"10.2515\/therapie\/2015027_bb0750","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/pds.1912","article-title":"Pharmacoepidemiological research using French reimbursement databases: yes we can!","volume":"19","author":"Martin-Latry","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.2515\/therapie\/2015027_bb0755","series-title":"Les personnes en affection longue dur\u00e9e au 31 d\u00e9cembre 2008","author":"Pa\u00efta","year":"2009"},{"key":"10.2515\/therapie\/2015027_bb0760","series-title":"Site internet de l\u2019Agence technique de l\u2019information m\u00e9dicale","author":"ATIH","year":"2013"},{"issue":"6","key":"10.2515\/therapie\/2015027_bb0765","doi-asserted-by":"crossref","first-page":"e304","DOI":"10.1016\/j.lpm.2011.01.021","article-title":"Mortality and hospital admissions rates and diagnosis among individuals with low income and full health insurance coverage in France, 2009","volume":"40","author":"Tuppin","year":"2011","journal-title":"Presse Med"},{"key":"10.2515\/therapie\/2015027_bb0770","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1177\/1352458511433305","article-title":"National estimate of multiple sclerosis incidence in France (2001-2007)","volume":"18","author":"Fromont","year":"2012","journal-title":"Mult Scler"},{"key":"10.2515\/therapie\/2015027_bb0775","series-title":"La s\u00e9curit\u00e9 routi\u00e8re en France [Bilan de l\u2019ann\u00e9e 2011]","author":"Observatoire national interminist\u00e9riel de s\u00e9curit\u00e9 routi\u00e8re","year":"2012"},{"key":"10.2515\/therapie\/2015027_bb0780","first-page":"477","article-title":"Victimes d\u2019accidents de la circulation : quelles \u00e9volutions?","volume":"47","author":"Gadegbeku","year":"2010"},{"key":"10.2515\/therapie\/2015027_bb0785","unstructured":"ANSM. Utilisation du baclof\u00e8ne dans le traitement de l\u2019alcoolod\u00e9pendance -Point d\u2019information Avril 2012 - Mise \u00e0 jour juin 2012. http:\/\/ansm.sante.fr\/content\/download\/41102\/535121\/version\/5\/file\/pi-121115-Baclfofene-maj.pdf Consult\u00e9 le 10 mars 2015 (5 pages)."},{"issue":"2","key":"10.2515\/therapie\/2015027_bb0790","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.euroneuro.2013.09.008","article-title":"Baclofen for alcohol dependence in France: incidence of treated patients and prescription patterns--a cohort study","volume":"24","author":"Dupouy","year":"2014","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.2515\/therapie\/2015027_bb0795","series-title":"\u00c9volution de la pr\u00e9valence des diff\u00e9rents profils d\u2019alcoolisation chez les adultes en France de 2002 \u00e0 2010","first-page":"185","author":"Com-Ruelle","year":"2013"},{"key":"10.2515\/therapie\/2015027_bb0800","series-title":"Morbidit\u00e9 et l\u00e9talit\u00e9 hospitali\u00e8res li\u00e9es aux maladies alcooliques du foie en 2008 en France","first-page":"191","author":"Jezewski-Serra","year":"2013"},{"key":"10.2515\/therapie\/2015027_bb0805","series-title":"L\u2019\u00e9tat de sant\u00e9 de la population en France - Rapport 2011","first-page":"131","article-title":"Pr\u00e9valence de l\u2019usage \u00e0 risque ou nocif de l\u2019alcool","author":"Direction de la recherche, des \u00e9tudes, de l\u2019\u00e9valuation et des statistiques","year":"2012"},{"issue":"6Pt 1","key":"10.2515\/therapie\/2015027_bb0810","first-page":"503","article-title":"Clinical and biological specificities of female alcoholism","volume":"28","author":"Limosin","year":"2002","journal-title":"Encephale"},{"key":"10.2515\/therapie\/2015027_bb0815","unstructured":"L\u2019Observatoire des Usages Internet de M\u00e9diam\u00e9trie. Source : M\u00e9diaFit, enqu\u00eate Omnibus exclusive \u2013 M\u00e9diam\u00e9trie \u2013 Terrain : du 4 avril 2013 au 10 avril 2013 Base : France, internautes \u00e2g\u00e9s de 15 ans et plus"},{"key":"10.2515\/therapie\/2015027_bb0820","unstructured":"Synth\u00e8se de 1085 t\u00e9moignages sur l\u2019alcoolisme et le baclof\u00e8ne : alcoolisme et baclof\u00e8ne : les premiers concern\u00e9s s\u2019expriment. Association BACLOFENE. http:\/\/www.baclofene.org\/enquete-baclofene Consult\u00e9 le 10 mars 2015."}],"container-title":["Therapies"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716310885?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716310885?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T12:02:08Z","timestamp":1554292928000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595716310885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S0040595716310885"],"URL":"https:\/\/doi.org\/10.2515\/therapie\/2015027","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]}}}